Multi-omics reveals key molecular and cellular features of advanced small cell lung cancers associated with distinct therapeutic opportunities - PubMed
5 hours ago
- #multi-omics
- #methylation profiling
- #small cell lung cancer
- Multi-omics study reveals molecular heterogeneity in advanced small cell lung cancer (SCLC).
- Methylation profiling identified four SCLC subgroups with distinct survival and tumor features.
- Group 1: Immune-enriched with CD8+ T cells and better survival.
- Group 2 (SCLC-A): Largest group, high SLFN11 and DLL3 expression, potential therapeutic targets.
- Group 3 (SCLC-N): High NEUROD1 expression, more fibroblasts.
- Group 4: Non-neuroendocrine features, worst survival, TACSTD2 as potential therapeutic target.
- SEZ6 highly expressed in most SCLCs, another potential therapeutic target.
- Methylation profiling can stratify SCLCs for tailored therapies and improve clinical outcomes.